目的观察抗胸腺细胞球蛋白（ＡＴＧ）和单克隆抗体ＣＤ３（ＯＫＴ３）对难治性排斥反应的疗效。方法８７例患者，其中ＡＴＧ组１３例，平均治疗总量１０００ｍｇ；ＯＫＴ３组７４例，平均治疗总量４５ｍｇ。结果ＡＴＧ组对急性加速性排斥反应治愈２例；对急性排斥反应治愈７例；总有效率为６９２３％（９／１３）。ＯＫＴ３组对急性加速性排斥反应治愈率为９０００％（２７／３０）；对急性排斥反应治愈率为９０４７％（３８／４２）；总有效率为９０２８％（６５／７２）与ＡＴＧ组有显著性差异（Ｐ＜００５）。其中对再次移植患者的各种急性排斥反应有效率为９１６７％（１１／１２）。结论ＯＫＴ３治疗难治性排斥反应的效果优于ＡＴＧ，尤其对再次移植患者，但对慢性排斥反应患者无效 Objective To observe the therapeutic effect of anti-thymocyte globulin (ATG) and monoclonal antibody-CD3 (OKT3) on refractory rejection. Methods 87 patients, including 13 cases of ATG group, the average total treatment of 1000mg; OKT3 group of 74 patients, the average treatment of 45mg. Results In ATG group, 2 cases of acute accelerated rejection were cured; 7 cases of acute rejection were cured; the total effective rate was 6923% (9/13). The cure rate of OKT3 group was 9000% (27/30) for acute accelerated rejection and 9047% (38/42) for acute rejection. The total effective rate was 9028% (65/72) ) Had significant difference with ATG group (P <005). Among them, the effective rate of various acute rejection in re-transplant patients was 91.67% (11/12). Conclusion OKT3 is superior to ATG in the treatment of refractory rejection, especially in patients with re-transplant, but not in patients with chronic rejection